Stay updated with breaking news from Acticor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies
Key milestones achieved in the two Phase 2/3 studies in stroke with glenzocimab: ACTISAVE study: more than 240 patients enrolled to date GREEN study: enrollment of the first patients
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies